Literature DB >> 26121099

Urinary Neutrophil Gelatinase-Associated Lipocalin Predicts Renal Injury Following Extracorporeal Membrane Oxygenation.

Alexandra J M Zwiers1, Karlien Cransberg, Yolanda B de Rijke, Joost van Rosmalen, Dick Tibboel, Saskia N de Wildt.   

Abstract

OBJECTIVE: To evaluate the course of urinary neutrophil gelatinase-associated lipocalin and urinary kidney injury molecule-1 levels in young children during extracorporeal membrane oxygenation and concomitant continuous hemofiltration. Furthermore, to evaluate whether these levels predict outcome.
DESIGN: Prospective observational cohort study from July 2010 to July 2013.
SETTING: ICU of a level III university children's hospital. PATIENTS: Thirty-one extracorporeal membrane oxygenation-treated children up to 1 year were included.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Patients were weaned from extracorporeal membrane oxygenation after a median of 162 hours (interquartile range, 83-304). Throughout the study, 58% of the patients met the criteria for acute kidney injury (i.e., Risk Injury Failure Loss End-Stage Renal Disease-Risk or higher defined as an increase in serum creatinine corresponding to ≥ 150% when compared with age-specific reference values). Levels of both biomarker patterns changed significantly throughout extracorporeal membrane oxygenation (urinary neutrophil gelatinase-associated lipocalin, p < 0.001 and urinary kidney injury molecule-1, p = 0.005, linear mixed model analyses). Urinary neutrophil gelatinase-associated lipocalin levels were already high before extracorporeal membrane oxygenation, whereas urinary kidney injury molecule-1 levels increased throughout the first extracorporeal membrane oxygenation day and peaked at 12-24 hours. Also, urinary neutrophil gelatinase-associated lipocalin levels at 12-24 hours of extracorporeal membrane oxygenation therapy were higher among patients with acute kidney injury post extracorporeal membrane oxygenation (p = 0.002, Mann-Whitney U test). Biomarker levels did not differ between survivors and nonsurvivors.
CONCLUSIONS: The increased urinary neutrophil gelatinase-associated lipocalin and urinary kidney injury molecule-1 levels confirm that renal tubular damage occurs in critically ill infants in need of extracorporeal membrane oxygenation. The fact that the maximal urinary neutrophil gelatinase-associated lipocalin levels were measured 24 hours earlier than urinary kidney injury molecule-1 supports the use of biomarker combinations rather than a single biomarker to identify patients at risk of acute kidney injury. Finally, since urinary neutrophil gelatinase-associated lipocalin levels at 12-24 hours of extracorporeal membrane oxygenation therapy were associated with acute kidney injury post extracorporeal membrane oxygenation, this marker may facilitate more timely adjustment of therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26121099     DOI: 10.1097/PCC.0000000000000476

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  3 in total

1.  The Incidence of Acute Kidney Injury and Its Effect on Neonatal and Pediatric Extracorporeal Membrane Oxygenation Outcomes: A Multicenter Report From the Kidney Intervention During Extracorporeal Membrane Oxygenation Study Group.

Authors:  Geoffrey M Fleming; Rashmi Sahay; Michael Zappitelli; Eileen King; David J Askenazi; Brian C Bridges; Matthew L Paden; David T Selewski; David S Cooper
Journal:  Pediatr Crit Care Med       Date:  2016-12       Impact factor: 3.624

2.  Prognostic value of endothelial biomarkers in refractory cardiogenic shock with ECLS: a prospective monocentric study.

Authors:  Tsung-Yu Tsai; Kun-Hua Tu; Feng-Chun Tsai; Yu-Yun Nan; Pei-Chun Fan; Chih-Hsiang Chang; Ya-Chung Tian; Ji-Tseng Fang; Chih-Wei Yang; Yung-Chang Chen
Journal:  BMC Anesthesiol       Date:  2019-05-15       Impact factor: 2.217

3.  Prognostic utility of neutrophil gelatinase associated lipocalin in cardiac ICU: A prospective study.

Authors:  Anubhuti Bhardwaj; Upma Narain; Arvind Gupta
Journal:  Indian Heart J       Date:  2022-03-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.